Get the Stockscreener App
0.478
1.44%
-0.007
Pre-market:
.45
-0.028
-5.86%
Hepion Pharmaceuticals Inc stock is traded at $0.478, with a volume of 12.96M.
It is down -1.44% in the last 24 hours and down -92.41% over the past month.
See More
Previous Close:
$0.485
Open:
$0.59
24h Volume:
12.96M
Relative Volume:
6.78
Market Cap:
$523.80K
Revenue:
-
Net Income/Loss:
$-22.70M
P/E Ratio:
-0.1091
EPS:
-4.38
Net Cash Flow:
$-26.07M
1W Performance:
-30.22%
1M Performance:
-92.41%
6M Performance:
-98.52%
1Y Performance:
-99.58%
1-Day Range:
$0.46
$0.70
1-Week Range:
$0.40
$0.989
52-Week Range:
$0.40
$145.00
Hepion Pharmaceuticals Inc Stock (HEPA) Company Profile
Name
Hepion Pharmaceuticals Inc
Sector
Industry
Phone
732-902-4000
Address
399 THORNALL STREET, EDISON
Compare HEPA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HEPA
Hepion Pharmaceuticals Inc
|
0.478 | 523.80K | 0 | -22.70M | -26.07M | -4.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Hepion Pharmaceuticals Inc Stock (HEPA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-20-20 | Resumed | ROTH Capital | Buy |
Hepion Pharmaceuticals Inc Stock (HEPA) Latest News
Before You Invest, Make Sure You Check This Hepion Pharmaceuticals Inc (NASDAQ: HEPA) Analysis - stocksregister.com
Hepion Pharmaceuticals Delays Annual Report Filing - TipRanks
Hepion Pharmaceuticals announces 1-for-50 reverse stock split - MSN
HEPA stock plunges to 52-week low, touches $0.67 By Investing.com - Investing.com UK
Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Price Down 7.2% – Here’s Why - Defense World
Hepion Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com South Africa
Hepion Pharmaceuticals faces potential Nasdaq delisting - Investing.com
Hepion Pharmaceuticals enacts reverse stock split - Investing.com
Hepion Pharmaceuticals Announces 1-for-50 Reverse Stock Split Effective March 17, 2025 - Nasdaq
Upcoming Stock Splits This Week (March 17 to March 21) – Stay Invested - The Globe and Mail
Hepion Pharmaceuticals Announces 1-for-50 Reverse Stock Split - ROI-NJ.com
Hepion Pharmaceuticals Announces 1-for-50 Reverse Stock Split To Maintain Nasdaq Listing - Nasdaq
Hepion Pharmaceuticals enacts reverse stock split to meet NASDAQ requirements - Investing.com Australia
Hepion Pharmaceuticals enacts reverse stock split to meet NASDAQ requirements By Investing.com - Investing.com South Africa
Hepion Pharmaceuticals Announces Reverse Stock Split - citybiz
Hepion Plans Massive 1:50 Reverse Split to Save NASDAQ ListingWhat Shareholders Must Know - StockTitan
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Benzinga India
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
An In-Depth Look At Hepion Pharmaceuticals Inc (HEPA) - Marketing Sentinel
HEPA stock plunges to 52-week low, touches $0.08 By Investing.com - Investing.com Australia
HEPA stock plunges to 52-week low, touches $0.08 - Investing.com
Hepion Pharmaceuticals releases unaudited balance sheet - Investing.com India
Hepion Pharmaceuticals Announces Publication in Expert Opinion on Investigational Drugs - ACCESS Newswire
HEPA stock touches 52-week low at $0.12 amid sharp decline - Investing.com Canada
Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431 - ACCESS Newswire
Hepion Pharmaceuticals (NASDAQ:HEPA) Shares Up 1.3% – Here’s Why - Defense World
The HEPA Stock Puzzle: Unraveling Hepion Pharmaceuticals Inc’s Fluctuating Performance - The InvestChronicle
A look at HEPA’s current quarter earnings estimates - US Post News
Evaluating the Impact of 3.43 Increase on Hepion Pharmaceuticals Inc’s (HEPA) Stock - The News Heater
Gaining Ground: Hepion Pharmaceuticals Inc (HEPA) Closes Higher at 0.17, Up 3.43 - The Dwinnex
Form DEF 14A Hepion Pharmaceuticals, For: Feb 07 - StreetInsider.com
An analyst sees good growth prospects for Hepion Pharmaceuticals Inc (HEPA) - SETE News
Hepion Pharmaceuticals Inc (HEPA) Stock: A Year of Decreases and Increases - The InvestChronicle
Understanding HEPA’s financial ratios: A beginner’s guide - US Post News
Metabolic Dysfunction-Associated Steatohepatitis Market to Register Stunning Growth at a CAGR of 17.9% in the US by 2034 | DelveInsight - PR Newswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket - Benzinga
Hepion Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference - ACCESS Newswire
Hepion Announces Closing of Public Offering of Common Stock - ACCESS Newswire
12 Health Care Stocks Moving In Friday's Pre-Market SessionAclarion (NASDAQ:ACON), Alumis (NASDAQ:ALMS) - Benzinga
Hepion Pharmaceuticals launches public offering for proceeds of up to $9M; shares tumble - MSN
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales - Benzinga
Nasdaq Surges 1.5%; Procter & Gamble Posts Upbeat Earnings - Benzinga
Stock market today: Star Fashion Culture Holdings jumped by 680.92% while Hepion Pharmaceuticals saw increase of 147.54% in early trading - Business Upturn
Hepion Pharmaceuticals launches $9 million stock offering - Investing.com India
Hepion Pharmaceuticals announces $9M public offering - TipRanks
Hepion Pharmaceuticals Announces $9.0 Million Public Offering - The Manila Times
Hepion Pharmaceuticals Announces $9M Public Offering with Dual Warrant Structure - StockTitan
HEPA stock touches 52-week low at $0.43 amid market challenges - Investing.com India
Hepion Pharmaceuticals Inc Stock (HEPA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):